Novartis Aktie

Novartis für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 907122 / ISIN: US66987V1098

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
07.11.2017 13:52:11

New Drugs Approved In October

(RTTNews) - Yet another month has gone by, and it's time again to take a look-back at the new drugs that successfully crossed the therapeutics finish line.

CAR-T therapy is garnering a lot of attention these days and another milestone was created in this exciting and evolving area of science last month when the second gene therapy for cancer was given the regulatory nod.

At the time of writing, 37 novel drugs were approved by the FDA for this year. This compares favorably with 22 novel drugs that were approved for the whole of 2016. Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before.

Click here for the list of new drugs approved in October.

Analysen zu Novartis AG (Spons. ADRS)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

AstraZeneca PLC (spons. ADRs) 57,50 -1,71% AstraZeneca PLC (spons. ADRs)
Gilead Sciences Inc. 87,85 -2,85% Gilead Sciences Inc.
Merck Co. 69,70 0,72% Merck Co.
Novartis AG (Spons. ADRS) 93,00 1,09% Novartis AG (Spons. ADRS)